| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Journal of Lipid Research, Vol 33, 995-1003, Copyright © 1992 by Lipid Research, Inc.
ARTICLES |
WJ McConathy, JC Gesquiere, H Bass, A Tartar, JC Fruchart and CS Wang
Protein Studies Program, Oklahoma Medical Research Foundation, Oklahoma City 73104.
In this study we have examined effects of synthetic polypeptide fragments of apoC-III on the kinetic properties of lipoprotein lipase (LPL) activity. Based on the loss of 79% of LPL-inhibitory activity after CNBr cleavage at the N-terminal portion of apoC-III and a systematic search for synthetic peptides with LPL-inhibitory activity spanning the apoC-III sequence, we concluded that the N-terminal domain is the most important in the modulation of LPL activity. In addition, there are multiple attachment sites in apoC-III for its interaction with LPL and these sites reside in the hydrophilic sequences of apoC- III. Probably for this reason the intact apo-CIII exhibited higher inhibitory potential than its peptide components. Based on the deduced inhibition constants derived for the synthetic apoC-III1-79 we concluded that apoC-III is likely to exhibit a physiological role in regulating LPL activity since the derived dissociation constants for the LPL-apoC-III interaction are within the physiological concentration range of plasma apoC-III. In addition, as the synthetic apoC-III1-79 lacks the carbohydrate moiety, we also concluded that the presence of the oligosaccharide in native apoC-III is not essential for its inhibitory activity on LPL. The fact that the I50 (concentration for inhibition of LPL at 50% activity) decreases for apoC-III-1 when assayed in the presence of apoC-II indicated that the activator actually caused an increased affinity between LPL and apoC-III and demonstrated that apoC-III does not compete for the activator site of apoC-II.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Qu, D. Su, J. Altomonte, A. Kamagate, J. He, G. Perdomo, T. Tse, Y. Jiang, and H. H. Dong PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1 Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E421 - E434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gerritsen, P. C. N. Rensen, K. E. Kypreos, V. I. Zannis, L. M. Havekes, and K. Willems van Dijk ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression J. Lipid Res., July 1, 2005; 46(7): 1466 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. P. Berbee, C. C. van der Hoogt, D. Sundararaman, L. M. Havekes, and P. C. N. Rensen Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL J. Lipid Res., February 1, 2005; 46(2): 297 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Olivieri, N. Martinelli, M. Sandri, A. Bassi, P. Guarini, E. Trabetti, F. Pizzolo, D. Girelli, S. Friso, P. F. Pignatti, et al. Apolipoprotein C-III, n-3 Polyunsaturated Fatty Acids, and "Insulin-Resistant" T-455C APOC3 Gene Polymorphism in Heart Disease Patients: Example of Gene-Diet Interaction Clin. Chem., February 1, 2005; 51(2): 360 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G Jackson, E. J Wolstencroft, P. A Bateman, P. Yaqoob, and C. M Williams Greater enrichment of triacylglycerol-rich lipoproteins with apolipoproteins E and C-III after meals rich in saturated fatty acids than after meals rich in unsaturated fatty acids Am. J. Clinical Nutrition, January 1, 2005; 81(1): 25 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Olivieri, A. Bassi, C. Stranieri, E. Trabetti, N. Martinelli, F. Pizzolo, D. Girelli, S. Friso, P. F. Pignatti, and R. Corrocher Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease J. Lipid Res., December 1, 2003; 44(12): 2374 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ando, T. Shimizugawa, S. Takeshita, M. Ono, M. Shimamura, R. Koishi, and H. Furukawa A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice J. Lipid Res., June 1, 2003; 44(6): 1216 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Couillard, M.-C. Vohl, J. C. Engert, I. Lemieux, A. Houde, N. Almeras, D. Prud'homme, A. Nadeau, J.-P. Despres, and J. Bergeron Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men J. Lipid Res., May 1, 2003; 44(5): 986 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shimizugawa, M. Ono, M. Shimamura, K. Yoshida, Y. Ando, R. Koishi, K. Ueda, T. Inaba, H. Minekura, T. Kohama, et al. ANGPTL3 Decreases Very Low Density Lipoprotein Triglyceride Clearance by Inhibition of Lipoprotein Lipase J. Biol. Chem., September 6, 2002; 277(37): 33742 - 33748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Olivieri, C. Stranieri, A. Bassi, B. Zaia, D. Girelli, F. Pizzolo, E. Trabetti, S. Cheng, M. A. Grow, P. F. Pignatti, et al. ApoC-III gene polymorphisms and risk of coronary artery disease J. Lipid Res., September 1, 2002; 43(9): 1450 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Morrisett, G. Abdel-Fattah, R. Hoogeveen, E. Mitchell, C. M. Ballantyne, H. J. Pownall, A. R. Opekun, J. S. Jaffe, S. Oppermann, and B. D. Kahan Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients J. Lipid Res., August 1, 2002; 43(8): 1170 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lins, C. Flore, L. Chapelle, P.J. Talmud, A. Thomas, and R. Brasseur Lipid-interacting properties of the N-terminal domain of human apolipoprotein C-III Protein Eng. Des. Sel., June 1, 2002; 15(6): 513 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Corella, M. Guillen, C. Saiz, O. Portoles, A. Sabater, J. Folch, and J. M. Ordovas Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: interaction with tobacco smoking and the APOE locus J. Lipid Res., March 1, 2002; 43(3): 416 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Jong, P. C. N. Rensen, V. E. H. Dahlmans, H. van der Boom, T. J. C. van Berkel, and L. M. Havekes Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice J. Lipid Res., October 1, 2001; 42(10): 1578 - 1585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Dallinga-Thie, M. Groenendijk, R. N. H. H. C. Blom, T. W. A. De Bruin, and E. De Kant Genetic heterogeneity in the apolipoprotein C-III promoter and effects of insulin J. Lipid Res., September 1, 2001; 42(9): 1450 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. L. Mamo, G. F. Watts, P. H. R. Barrett, D. Smith, A. P. James, and S. Pal Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression? Am J Physiol Endocrinol Metab, September 1, 2001; 281(3): E626 - E632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Grundy Cholesterol-Lowering Therapy in Secondary Prevention: Remaining Issues J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2092 - 2098. [Full Text]
|
|
|
|
|
|
E. D. Breyer, N.-A. Le, X. Li, D. Martinson, and W. V. Brown Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size J. Lipid Res., October 1, 1999; 40(10): 1875 - 1882. [Abstract] [Full Text]
|
|
|
|
|
|
M. Groenendijk, R. M. Cantor, N. H. H. C. Blom, J. I. Rotter, T. W. A. de Bruin, and G. M. Dallinga-Thie Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia J. Lipid Res., June 1, 1999; 40(6): 1036 - 1044. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. C. Jong, M. H. Hofker, and L. M. Havekes Role of ApoCs in Lipoprotein Metabolism : Functional Differences Between ApoC1, ApoC2, and ApoC3 Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 472 - 484. [Full Text] [PDF]
|
|
|
|
|
|
H. Jansen, G. Chu, C. Ehnholm, J. Dallongeville, V. Nicaud, and P. J. Talmud The T Allele of the Hepatic Lipase Promoter Variant C-480T Is Associated With Increased Fasting Lipids and HDL and Increased Preprandial and Postprandial LpCIII:B : European Atherosclerosis Research Study (EARS) II Arterioscler. Thromb. Vasc. Biol., February 1, 1999; 19(2): 303 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Andersson, Z. Majd, A.-M. Lefebvre, G. Martin, A. V. Sechkin, V. Kosykh, J.-C. Fruchart, J. Najib, and B. Staels Developmental and Pharmacological Regulation of Apolipoprotein C-II Gene Expression : Comparison With Apo C-I and Apo C-III Gene Regulation Arterioscler. Thromb. Vasc. Biol., January 1, 1999; 19(1): 115 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Zsigmond, Y. Fuke, L. Li, K. Kobayashi, and L. Chan Resistance of chylomicron and VLDL remnants to post-heparin lipolysis in ApoE-deficient mice: the role of apoE in lipoprotein lipase-mediated lipolysis in vivo and in vitro J. Lipid Res., September 1, 1998; 39(9): 1852 - 1861. [Abstract] [Full Text]
|
|
|
|
|
|
C. J. Mann, A. A. Troussard, F. T. Yen, N. Hannouche, J. Najib, J.-C. Fruchart, V. Lotteau, P. Andre, and B. E. Bihain Inhibitory Effects of Specific Apolipoprotein C-III Isoforms on the Binding of Triglyceride-rich Lipoproteins to the Lipolysis-stimulated Receptor J. Biol. Chem., December 12, 1997; 272(50): 31348 - 31354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C.N. Rensen and T. J.C. van Berkel Apolipoprotein E Effectively Inhibits Lipoprotein Lipase-mediated Lipolysis of Chylomicron-like Triglyceride-rich Lipid Emulsions in Vitro and in Vivo J. Biol. Chem., June 21, 1996; 271(25): 14791 - 14799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hasler-Rapacz, M. F. Prescott, J. Von Linden-Reed, J. M. Rapacz Jr, Z. Hu, and J. Rapacz Elevated Concentrations of Plasma Lipids and Apolipoproteins B, C-III, and E Are Associated With the Progression of Coronary Artery Disease in Familial Hypercholesterolemic Swine Arterioscler. Thromb. Vasc. Biol., May 1, 1995; 15(5): 583 - 592. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
